Allakos (ALLK) Stock Price, News & Analysis

Company Overview

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Key Stats

• Today's Range: $0.33 to $0.33
• 50-Day Range: $0.33 to $0.33
• 52-Week Range: $0.22 to $1.56
• Volume: N/A
• Average Volume: 1.25 million shs
• Market Capitalization: $29.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

Allakos Stock Analysis - MarketRank™

Allakos scored higher than 65% of companies evaluated by MarketBeat, and ranked 346th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Allakos has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Allakos has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Allakos are expected to grow in the coming year, from ($1.17) to ($0.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Allakos is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Allakos is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Allakos has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ALLK.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Allakos does not currently pay a dividend.

Dividend Growth

Allakos does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.86

Short Interest

There is no current short interest data available for ALLK.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Allakos insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.12% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.64% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALLK Stock Analysis - Frequently Asked Questions

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) released its earnings results on Wednesday, November, 6th. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01.

When did Allakos IPO?

Allakos (ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

What other stocks do shareholders of Allakos own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Allakos investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), Jabil (JBL) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 8/31/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALLK
• CIK: 1564824
• Web: www.allakos.com
• Phone: (650) 597-5002
• Fax: N/A
• Employees: 190
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Allakos: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +811.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$185.70 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -140.87%
• Return on Assets: -86.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.08
• Quick Ratio: 6.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.93 per share
• Price / Book: 0.17

Miscellaneous

• Outstanding Shares: 90,377,000
• Free Float: 74,942,000
• Market Cap: $29.74 million
• Optionable: Optionable
• Beta: 0.15